Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis.
The antiresorptive drug elcatonin (ECT) is known to relieve pain in postmenopausal women with osteoporosis. A prospective open-labeled trial was conducted to compare the effects of short-term combined treatment with alendronate (ALN) and ECT on bone mineral density (BMD) and bone turnover with those of single treatment with ALN in postmenopausal women with osteoporosis. Two hundred and five postmenopausal osteoporotic women (mean age: 70 years) were recruited in our outpatient clinic. Forty-six women with back pain were treated with ALN and ECT (intramuscular, 20 units a week), and 159 women without obvious back pain were treated with ALN alone. The lumbar BMD, urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP) were measured during the six-month treatment period. The baseline characteristics, except for age, body weight and number of patients with prevalent vertebral fractures, were not significantly different between the two groups. The mean increase rate in the lumbar BMD at six months was similar in the ALN (+4.41%) and ALN+ECT (+5.15%) groups, following similar reduction rates in urinary NTX levels (-40.2% and -43.0%, respectively, at three months) and serum ALP levels (-19.0% and -19.7%, respectively, at six months). These results were consistent even after adjustments for age, body weight, and number of patients with prevalent vertebral fractures. The present study in postmenopausal osteoporotic women confirmed that the effects of short-term combined treatment with ALN and ECT on lumbar BMD and bone turnover in patients with back pain appeared to be comparable to those of single treatment with ALN in patients without obvious back pain.
Iwamoto
Jun
J
Institute for Integrated sports Medicine, Keio University school of Medicine, Tokyo, Japan.
Uzawa
Mitsuyoshi
M
Sato
Yoshihiro
Y
Takeda
Tsuyoshi
T
Matsumoto
Hideo
H
Bone. 2001 Nov;29(5):437-41
11704495
Yonsei Med J. 2004 Aug 31;45(4):676-82
15344210
J Bone Miner Metab. 2005;23(2):167-73
15750696
J Bone Miner Metab. 2005;23(3):238-42
15838627
Mayo Clin Proc. 2005 Mar;80(3):379-88
15757020
Osteoporos Int. 1999;10(3):183-92
10525709
J Clin Endocrinol Metab. 2002 Apr;87(4):1586-92
11932287
Bone. 1999 May;24(5 Suppl):73S-79S
10321934
Clin Interv Aging. 2008;3(3):483-9
18982918
J Bone Miner Metab. 2005;23(2):97-104
15750686
Clin Rheumatol. 2007 Feb;26(2):161-7
16565894
Curr Med Res Opin. 2006 May;22(5):919-28
16709313
J Bone Miner Metab. 2001;19(6):331-7
11685647
Yonsei Med J. 2008 Feb 29;49(1):119-28
18306478
Endocrinology. 1981 Feb;108(2):698-702
7449744
Pharmacol Biochem Behav. 1998 Jun;60(2):371-6
9632219
Gen Pharmacol. 1995 May;26(3):641-7
7789740
Experientia. 1976 Sep 15;32(9):1104-6
971732
J Bone Miner Metab. 2005;23(5):382-8
16133688
Yonsei Med J. 2005 Dec 31;46(6):750-8
16385649
Am J Med. 2002 Mar;112(4):281-9
11893367
Expert Opin Pharmacother. 2007 Nov;8(16):2743-56
17956196